What is glucocorticoid withdrawal syndrome and how does it relate to secondary adrenal insufficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Glucocorticoid Withdrawal Syndrome and Its Relationship to Adrenal Insufficiency

Glucocorticoid withdrawal syndrome (GWS) is a distinct clinical entity that occurs when tapering supraphysiologic glucocorticoid doses, characterized by symptoms similar to adrenal insufficiency but occurring while patients are still on doses above physiologic replacement levels—meaning it is NOT due to true cortisol deficiency. 1

Key Distinction Between GWS and Adrenal Insufficiency

The critical difference lies in the glucocorticoid dose at which symptoms occur:

  • Glucocorticoid Withdrawal Syndrome: Symptoms develop when reducing doses that remain supraphysiologic (above prednisone 5-6 mg/day or hydrocortisone 25 mg/day). By definition, patients still have adequate exogenous glucocorticoid coverage, so true adrenal insufficiency cannot be the cause. 1

  • Glucocorticoid-Induced Adrenal Insufficiency (Secondary AI): This represents actual HPA axis suppression where the body cannot produce sufficient cortisol. This becomes clinically relevant only when doses approach or fall below physiologic replacement levels (prednisone 4-6 mg/day or hydrocortisone 15-25 mg/day). 1

Clinical Presentation

Both conditions share overlapping symptoms, making differentiation challenging 1:

  • Myalgias and weakness
  • Fatigue
  • Sleep disturbances
  • Mood changes
  • Gastrointestinal symptoms

The key clinical clue is the total daily glucocorticoid dose. For example, a patient on prednisone 20-40 mg who develops fatigue and myalgias during taper is experiencing GWS, not adrenal insufficiency—they have more than adequate glucocorticoid coverage. Concerns for true adrenal insufficiency only arise when the taper reaches 5-7.5 mg prednisone. 1

Pathophysiology

GWS occurs due to physical dependence on supraphysiologic glucocorticoid levels, thought to result from an abrupt decrease in glucocorticoid exposure leading to increased inflammatory cytokines. 1 The body has adapted to high glucocorticoid levels through multiple mechanisms including HPA axis suppression, altered glucocorticoid receptor signaling, disrupted circadian rhythms, and changes in immune/inflammatory pathways. 2

Most patients with GWS do have concomitant biochemical adrenal insufficiency (HPA axis suppression), but the withdrawal symptoms occur before reaching doses low enough to cause clinical adrenal insufficiency. 1

Management Approach

For GWS (doses above physiologic):

  • Slow, gradual tapering is the only effective intervention 1
  • When GWS is severe, temporarily increase the dose to the most recent tolerated level, then resume tapering over a longer duration 1
  • Patients with features of exogenous Cushing syndrome are more likely to experience severe GWS and require slower tapers 1
  • Tapering can be more rapid within the supraphysiologic range, but must slow considerably once approaching physiologic doses 1

For True Adrenal Insufficiency (at physiologic doses):

Once reaching physiologic doses (prednisone 4-6 mg/day), assess HPA axis recovery with morning cortisol (8-9 AM, 24 hours after last dose) 1:

  • >300 nmol/L (10 μg/dL): HPA axis recovered, can safely stop glucocorticoids 1
  • 150-300 nmol/L (5-10 μg/dL): Continue physiologic replacement, recheck in weeks to months 1
  • <150 nmol/L (5 μg/dL): Persistent adrenal insufficiency, continue physiologic replacement, recheck in several months 1

Critical Pitfalls

  1. Do not test for adrenal insufficiency while on supraphysiologic doses—it provides no useful information and testing is not indicated until reaching physiologic dose ranges. 1

  2. Do not confuse GWS symptoms with disease flare—both can present similarly, but the timing relative to dose reduction is key.

  3. Avoid abrupt discontinuation in patients on long-term high-dose therapy—they are at highest risk for severe GWS and benefit from gradual tapering. 1

  4. Remember that biochemical adrenal insufficiency is common but clinically significant adrenal crisis is rare in this population—the risk of adrenal crisis remains very low even with biochemical suppression. 1

  5. Patients with morning cortisol near 300 nmol/L may still have suboptimal stress response—use clinical judgment and provide stress dose coverage for major stressors (sepsis, trauma, surgery) even if morning cortisol suggests recovery. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.